Company / Operating Income
Abbott Laboratories Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$8.1B
FY2025
5-year range
$4.5B / $8.4B
FY2021-FY2025
Trend
+18.0%
vs FY2024
Sector context
#3 of 156
Health Care
What the data says
Among 156 Health Care companies, Abbott Laboratories is in the top 2% for operating income. Operating Income has fluctuated over the past 10 years, ranging from $2.6B in FY2016 to $8.4B in FY2023.
Based on SEC 10-K filings.
$8.1B in FY2025 with a 5-year CAGR of +17.1%. Ranks 3rd among 156 companies in Health Care.
Declined from $8.4B to $8.1B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +14.6%
- 5-Year CAGR
- +17.1%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 156This company $8.1B Sector average $733.1M
▼
+998.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +17.1%, indicating consistent growth.
- In FY2025, operating income increased 18.0% year-over-year.
- Ranks #3 out of 156 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.1B | +18.0% |
| FY2024 | $6.8B | -19.0% |
| FY2023 | $8.4B | +57.3% |
| FY2022 | $5.4B | +18.2% |
| FY2021 | $4.5B | +24.2% |
| FY2020 | $3.6B | -19.5% |
| FY2019 | $4.5B | +49.8% |
| FY2018 | $3.0B | +5.5% |
| FY2017 | $2.9B | +10.3% |
| FY2016 | $2.6B | +21.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026